228 related articles for article (PubMed ID: 12950233)
1. Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab.
Kennedy GA; Seymour JF; Wolf M; Januszewicz H; Davison J; McCormack C; Ryan G; Prince HM
Eur J Haematol; 2003 Oct; 71(4):250-6. PubMed ID: 12950233
[TBL] [Abstract][Full Text] [Related]
2. Mycosis fungoides/Sézary syndrome: a report of three cases treated with Campath-1H as salvage treatment.
Capalbo S; Delia M; Dargenio M; Liso A; Diomede D; Garofalo L; Liso V
Med Oncol; 2003; 20(4):389-96. PubMed ID: 14716037
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center.
Querfeld C; Mehta N; Rosen ST; Guitart J; Rademaker A; Gerami P; Kuzel TM
Leuk Lymphoma; 2009 Dec; 50(12):1969-76. PubMed ID: 19860617
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome.
Lundin J; Hagberg H; Repp R; Cavallin-Ståhl E; Fredén S; Juliusson G; Rosenblad E; Tjønnfjord G; Wiklund T; Osterborg A
Blood; 2003 Jun; 101(11):4267-72. PubMed ID: 12543862
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H).
Gautschi O; Blumenthal N; Streit M; Solenthaler M; Hunziker T; Zenhäusern R
Eur J Haematol; 2004 Jan; 72(1):61-3. PubMed ID: 14962265
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia--change of regimen needed?
Rieger K; Von Grünhagen U; Fietz T; Thiel E; Knauf W
Leuk Lymphoma; 2004 Feb; 45(2):345-9. PubMed ID: 15101722
[TBL] [Abstract][Full Text] [Related]
7. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.
Lenihan DJ; Alencar AJ; Yang D; Kurzrock R; Keating MJ; Duvic M
Blood; 2004 Aug; 104(3):655-8. PubMed ID: 15073032
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas.
de Masson A; Guitera P; Brice P; Moulonguet I; Mouly F; Bouaziz JD; Battistella M; Madelaine I; Roux J; Ram-Wolff C; Cayuela JM; Bachelez H; Bensussan A; Michel L; Bagot M
Br J Dermatol; 2014 Mar; 170(3):720-4. PubMed ID: 24438061
[TBL] [Abstract][Full Text] [Related]
9. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome.
Lundin J; Kennedy B; Dearden C; Dyer MJ; Osterborg A
Blood; 2005 May; 105(10):4148-9. PubMed ID: 15867423
[No Abstract] [Full Text] [Related]
10. Alemtuzumab in Sézary syndrome: efficient but not innocent.
Ure UB; Ar MC; Salihoglu A; Guner SI; Baran A; Oguz O; Ferhanoglu B
Eur J Dermatol; 2007; 17(6):525-9. PubMed ID: 17951134
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Sézary Syndrome With Alemtuzumab: A Series of 5 Cases and a Review of the Literature.
del Alcázar-Viladomiu E; Tuneu-Valls A; López-Pestaña A; Vidal-Manceñido MJ
Actas Dermosifiliogr; 2015 Sep; 106(7):e33-9. PubMed ID: 25960287
[TBL] [Abstract][Full Text] [Related]
12. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.
Pangalis GA; Dimopoulou MN; Angelopoulou MK; Tsekouras C; Vassilakopoulos TP; Vaiopoulos G; Siakantaris MP
Med Oncol; 2001; 18(2):99-107. PubMed ID: 11778765
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab treatment for Sézary syndrome: A single-center experience.
Novelli S; García-Muret P; Sierra J; Briones J
J Dermatolog Treat; 2016; 27(2):179-81. PubMed ID: 26329989
[TBL] [Abstract][Full Text] [Related]
14. Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer.
Ho AD; Suciu S; Stryckmans P; De Cataldo F; Willemze R; Thaler J; Peetermans M; Döhner H; Solbu G; Dardenne M; Zittoun R
Semin Oncol; 2000 Apr; 27(2 Suppl 5):52-7. PubMed ID: 10877053
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.
Khodadoust MS; Rook AH; Porcu P; Foss F; Moskowitz AJ; Shustov A; Shanbhag S; Sokol L; Fling SP; Ramchurren N; Pierce R; Davis A; Shine R; Li S; Fong S; Kim J; Yang Y; Blumenschein WM; Yearley JH; Das B; Patidar R; Datta V; Cantu E; McCutcheon JN; Karlovich C; Williams PM; Subrahmanyam PB; Maecker HT; Horwitz SM; Sharon E; Kohrt HE; Cheever MA; Kim YH
J Clin Oncol; 2020 Jan; 38(1):20-28. PubMed ID: 31532724
[TBL] [Abstract][Full Text] [Related]
16. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.
Lundin J; Osterborg A; Brittinger G; Crowther D; Dombret H; Engert A; Epenetos A; Gisselbrecht C; Huhn D; Jaeger U; Thomas J; Marcus R; Nissen N; Poynton C; Rankin E; Stahel R; Uppenkamp M; Willemze R; Mellstedt H
J Clin Oncol; 1998 Oct; 16(10):3257-63. PubMed ID: 9779699
[TBL] [Abstract][Full Text] [Related]
17. Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients.
Bernengo MG; Quaglino P; Comessatti A; Ortoncelli M; Novelli M; Lisa F; Fierro MT
Haematologica; 2007 Jun; 92(6):784-94. PubMed ID: 17550851
[TBL] [Abstract][Full Text] [Related]
18. Immunophenotypic stability of Sézary cells by flow cytometry: usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy.
Vaughan J; Harrington AM; Hari PN; Kroft SH; Olteanu H
Am J Clin Pathol; 2012 Mar; 137(3):403-11. PubMed ID: 22338052
[TBL] [Abstract][Full Text] [Related]
19. Transformation of Sézary syndrome into CD30+ anaplastic large T-cell lymphoma after alemtuzumab therapy with evidence of clonal unity.
Nevet MJ; Zuckerman T; Sahar D; Bergman R
Am J Dermatopathol; 2015 Jan; 37(1):73-7. PubMed ID: 25548993
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
Ferrajoli A; O'Brien SM; Cortes JE; Giles FJ; Thomas DA; Faderl S; Kurzrock R; Lerner S; Kontoyiannis DP; Keating MJ
Cancer; 2003 Aug; 98(4):773-8. PubMed ID: 12910522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
